Percheron Therapeutics (ASX:PER)
ASX announcement history & article coverage
Transparent by design.
Announcments by Percheron Therapeutics (ASX:PER) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change of Director's Interest Notice
Notice under S708A
Application for quotation of securities - PER
Application for quotation of securities - PER
Change of Director's Interest Notice
Notification regarding unquoted securities - PER
Results of Annual General Meeting
Annual General Meeting - Management Presentation
Annual General Meeting - Chair Address
Proposed issue of securities - PER
Final Director's Interest Notice
Initial Director's Interest Notice
Dr Michael Baker Commences as CEO and MD
Notice under S708A
Application for quotation of securities - PER
2026 Notice of Annual General Meeting
Percheron Therapeutics Limited Corporate Presentation
Proposed issue of securities - PER
Proposed issue of securities - PER
Proposed issue of securities - PER
Percheron raises $2.3m to fully fund clinical trial in AML
$2.3 Million Placement to Fund AML Clinical Trial
Initial Director's Interest Notice
Transitional appointment of Executive Director
Change of Director's Interest Notice
Notification of cessation of securities - PER
Percheron receives $0.70m R&D Tax Incentive Rebate
Trading Halt
Vanderbilt Health to conduct clinical trial of HMBD-002
Percheron Therapeutics to start clinical trial of HMBD-002 in AML with Vanderbilt Health
Appendix 4E and Annual Report
Percheron Therapeutics reports FY2026 loss of AUD 4.79m, advances HMBD-002 oncology drug, CEO transition announced
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report
Percheron Therapeutics narrows FY2026 loss, advances HMBD-002 oncology drug with phase II trial planned
Application for quotation of securities - PER
Notice of date of AGM and other relevant dates
Percheron Therapeutics Announces CEO Succession
Percheron Therapeutics appoints Dr Michael Baker as new CEO, Dr James Garner to step down
Quarterly Activities Report and Appendix 4C
Percheron Therapeutics advances HMBD-002 with WHO pINN, $2.2M funding, and clinical progress